Grants Funded

Since 2008, support from Good Cookies like YOU has helped Cookies for Kids' Cancer fund 91 childhood cancer research grants, leading to 36 promising new treatments and clinical trials available to children fighting cancer TODAY.

Cookies for Kids' Cancer is committed to funding promising research for less toxic therapies for children battling cancer. Each year grants are given under the guidance of the Medical Advisory Board. The mission of the organization is to fund as much promising research as possible, while keeping administrative costs as low as possible. With 8 full years as a non-profit complete, Cookies for Kids' Cancer is now eligible for review by Charity Navigator. If you have questions about how Cookies for Kids' Cancer makes grants or allocates funds, please email emily@beagoodcookie.org.

Treatments Now in Clinical Trial:

Memorial Sloan-Kettering Cancer Center

HU3F8 antibody treatment

Saponin adjuvant for GD2 conjugate vaccine

Convection-enhanced delivery of 124I-8H9 – Brainstem glioma

Children's Hospital of Philadelphia

Engineered t cell therapy - recurrent neuroblastoma & b cell malignancies

Phase I trial of MK1775, approved and activated for accrual

Texas Children's Cancer Center

Phase I/II trials of ABT-888 plus XRT - pediatric brain tumors

Immunotherapy with dual-specific NKT cells - Neuroblastoma

St. Jude Children's Research Hospital

CD-20 targeted therapy - Leukemia

Anti-GD2 monoclonal antibody therapy - Neuroblastoma

Dana-Farber Cancer Institute

Targeting of Cdk4 signaling in pediatric Rhabdoid tumors

Phase II study of clofarabine in refractory Langerhans cell histiocytosis


As of 2013, a portion of funds raised are also used to MATCH, dollar for dollar, the federal allowance per child enrolled in the Children's Oncology Group's Phase I & Pilot Consortium.

COG Phase 1/Pilot Consortium Studies:

A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), a Replication-Competent Picornavirus, in Pediatric Patients with Recurrent/Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features

A Phase I Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors

A Phase 1 Study of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

A Phase 1 Study of JAK Inhibition (Ruxolitinib) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND#112603) in Children with Relapsed or Refractory Solid Tumors

A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma

A Phase 1 Study of Temsirolimus (CCI-779, IND#61010) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma

A Phase 1 Study of AMG 386 (trebananib, IND#114215), an Angiopoietin Neutralizing Peptibody, in Children with Relapsed or Refractory Solid Tumors, including CNS Tumors.

A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, including CNS Tumors

A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

A Phase 1 Study of the TEM-1 antibody, MORAb-004 (IND# 103821), in Children with Recurrent or Refractory Solid Tumors

A Phase 1 Study of AZD1775 (MK-1775, IND#116459) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas

A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# 123101) in Children with Recurrent or Refractory Solid Tumors

A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas

A Phase 1/2 Trial of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma

A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

A Phase 1/2 Study of MK-1775 (AZD1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab


Research Grants Funded to Date:

AMOUNT CENTER RESEARCHER GRANT

2016

$200,000

Children's Hospital of Philadelphia

Dr. Carolyn Felix

Ribavirin-Epigenetic Therapy Combinations to Combat MLL-R Infant ALL

$200,000

Children's Hospital of Philadelphia

Dr. Yael Mosseé

Clinical Development of Next Generation ALK inhibitor lorlatinib for patients with ALK-driven neuroblastomas

$200,000

Dana-Farber Cancer Institute

Dr. Scott Armstrong

New combination therapies for MLL-rearranged Acute Lymphoblastic Leukemia

$200,000

Dana-Farber Cancer Institute

Dr. Nicholas Haining

Discovering somatic mutations in cancer that cause resistance to immunotherapy

$200,000

Memorial Sloan-Kettering Cancer Center

Dr. Brian Kushner

Phase II Study of Humanized 3F8 Anti-GD2 Monoclonal Antibody and GM-CSF in Patients with Refractory or Relapsed High-Risk Neuroblastoma

$200,000

St. Jude Children's Research Hospital

Dr. Sara Federico

A pilot induction regimen incorporating dinutuximab for the treatment of newly diagnosed high-risk neuroblastoma

$200,000

Texas Children's Cancer Center

Dr. Carl Allen

Correlative Biology to Predict Response and Toxicity in Children Receiving Immunotherapy and Cytotoxic T Cell Therapy for Post- Transplant Lymphoproliferative Disease

$200,000

Texas Children's Cancer Center

Dr. Ronald Bernardi

Combined inhibition of WEE1 and oncogenic receptor tyrosine kinases as a therapeutic strategy to overcome redundant mitotic checkpoint control in neuroblastoma

$428,047

Texas Children's Cancer Center

Dr. Andras Heczey

T cells expressing an optimized Glypican-3- specific CAR for children with solid tumors

$200,000

Texas Children's Cancer Center

Dr. Ann Leen

Adoptive T-cell therapy for ALL targeting multiple tumor associated antigens

$200,000

Texas Children's Cancer Center

Dr. Jason Shohet

A Safety Pilot Study of High Risk Induction Chemotherapy for Neuroblastoma without Prophylactic Administration of Myeloid Growth Factors (SPRING).

2015

$500,000

COG

Children's Oncology Group

Full payment for $4k per child enrolled in 2015 to COG's Phase 1 Clinical Trial Consortium. 2x the Federal Government's per child allocation

$150,000

Children's Oncology Group

Dr. Michael LaQuaglia

Prospective study of outcomes after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis

$200,000

Children's Hospital of Philadelphia

Dr. Yael Moseé

Preclinical and Clinical Development of Next Generation ALK Inhibitor, PF-06463922, or ALK driven neuroblastoma

$200,000

Memorial Sloan Kettering Cancer Center

Dr. Kim Kramer

A phase I study of convection-enhanced delivery of 124I-8H9 for patients with non-progressive diffuse pontine gliomas (DIPG) previously treated with external beam radiation therapy

$200,000

Memorial Sloan Kettering Cancer Center

Dr. Shakeel Modak

The development and preclinical validation of site-specifically radiolabeled hu3F8 for PET Imaging and radioimmunotherapy of neuroblastoma

$100,000

St. Jude Children's Research Hospital

Dr. Jeffrey Rubnitz

Pilot study of microtransplantation in pediatric patients with refractory or relapsed acute myeloid leukemia

$200,000

Baylor College of Medicine

Dr. Nabil Ahmed

Adoptive Immunotherapy for Pediatric Sarcoma

$200,000

Baylor College of Medicine

Dr. Donald Parsons

Evaluating the Impact of Tumor Heterogeneity and Clonal Evolution on Clinical Genomic Testing for Pediatric Solid Tumor Patients

$200,000

Baylor College of Medicine

Dr. Carl Allen

Redefining Standard of Care for Front-line Therapy for Langerhans Cell Histiocytosis (LCH)

$200,000

Baylor College of Medicine

Dr. Jason Shohet

Characterization and targeting of neuroblastoma Cancer Stem Cells (CSCs)

2014

$100,000

Children's Hospital of Philadelphia

Dr. Maris

Identifying novel drug combinations for neuroblastoma

$100,000

Children's Hospital of Philadelphia

Dr. Aplenc

Chimeric antigen receptor T cell immunotherapy for pediatric acute myeloid leukemia

$150,000*

Children's Oncology Group

Dr. LaQuaglia

Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *Second year of 3-year project totaling $450,000.

$100,000

Dana-Farber Cancer Institute

Dr. Dranoff

A Phase I Study of irradiated GM-CSF secreting autologous neuroblastoma cell vaccine (GVAX) for relapsed or refractory neuroblastoma

$200,000

Memorial Sloan Kettering Cancer Center

Dr. Modak

Targeting pediatric solid tumors: A pilot study of Radiolmmuno-PET imaging using 124I-Humanized 3F8

$100,000

Memorial Sloan Kettering Cancer Center

Dr. Kushner

Bivalent vaccine plus beta-glucan for high-risk neuroblastoma in first remission

$100,000

St. Jude Children's Research Hospital

Dr. Mullighan

Identifying novel drivers and childhood acute lymphoblastic leukemia disease and resistance

$100,000

Texas Children's Cancer Center

Dr. Zage

A Phase I Study of vandetanib (CaprelsaTM) in combination with 13-cis-retinoic acid in children with relapsed or refractory solid tumors

$100,000

Texas Children's Cancer Center

Dr. Gottschalk

IL13Ra2-CAR T-cell therapy for pediatric high grade glioma

2013

$100,000

Children's Hospital Of Philadelphia

Dr. Nichols

Novel cell-based therapy for b cell leukemias and lymphomas

$100,000

Children's Hospital Of Philadelphia

Dr. Thomas-Tikhonenko

Decreasing resistance to chemotherapies in pediatric lymphomas, and decreasing sensitivities and effects related to the chemotherapy drug Doxorubicin

$350,000

Children's Oncology Group

Matching federal funds per child enrolled in Phase I clinical trials

$150,000*

Children's Oncology Group

Dr. LaQuaglia

Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *First year of 3-year project totaling $450,000.

$100,000

Dana-Farber Cancer Institute

Dr. Stegmaier

New treatments for neuroblastoma by targeting the Epigenome

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Retargeting t cells using bispecific antibody against receptor Tyrosine Kinase-like orphan receptors 2 (Ror2) in solid tumors

$100,000

St. Jude Children's Research Hospital

Dr. Inaba

Genetic characterization and therapeutic targeting of pediatric mixed phenotype acute leukemia

$100,000

Texas Children's Cancer Center

Dr. Berg

Phase I trial of Sgt-53, a novel nanoparticle therapy, for children with refractory or recurrent solid tumors

$100,000

Texas Children's Cancer Center

Dr. Metelitsa

Phase I clinical trial of a novel immune therapy using dual-specific Nkt cells for children with neuroblastoma

2012

$350,000

Children's Oncology Group

Matching federal funds per child enrolled in Phase I clinical trials

$100,000

Children's Hospital Of Philadelphia

Dr. Attiyeh

Xpo1 Inhibition in neuroblastoma

$100,000

Children's Hospital Of Philadelphia

Dr. Bassing

Targeting Bcl11b Haploin sufficient lymphoid tumors 6

$100,000

Dana-Farber Cancer Institute

Dr. Roberts

Targeting of Cdk4 signaling in pediatric Rhabdoid tumors

$100,000

Dana-Farber Cancer Institute

Dr. Galiando

Phase II study of clofarabine in refractory Langerhans cell histiocytosis

$100,000

Dana-Farber Cancer Institute

Dr. Shusterman

Csf producing whole tumor vaccine for neurblastoma

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Dual specific human monoclonal antibody targeting IGF-I and IGF-II for pediatric cancers

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Kramer

Delivery of 124-I-8h9 non-progressive diffuse Pontine Gliomas.

$100,000

St. Jude Children's Research Hospital

Dr. Furman

Hu14.18322a + Multi-Modality treatment for neuroblastoma

$100,000

Texas Children's Cancer Center

Dr. Gottschalk

Fap-targeted t cell therapy for osteosarcoma

2011

$100,000

St. Jude Children's Research Hospital

Dr. Gilbertson

Rapid and accurate diagnosis of Medolloblastoma subtypes in trials

$100,000

Children's Hospital Of Philadelphia

Dr. Maris

Molecular oncology for pediatric cancers

$100,000

Children's Hospital Of Philadelphia

Dr. Weiss

Modeling juvenile myelomonocytic Leukemia patient Ips cells

$100,000

Dana-Farber Cancer Institute

Dr. Stegmaier

Validation of fak therapeutic target in Ewings Sarcoma

$100,000

Dana-Farber Cancer Institute

Dr. George

Development of dendritic call vaccine against Alk-Positive

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

A safe, potent Saponin adjuvant for Gd2 conjugated vaccine for neuroblastoma

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. LaQuaglia

Phase I trial of Hepatic Artery Infusion/neuroblastoma tumors in the liver

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$100,000

Texas Children's Cancer Center

Dr. Metelitsa

Immunotherapy of neuroblastoma with dual-specific Nkt cells

$100,000

Texas Children's Cancer Center

Dr. Nuchtern

Genomic anatomy of chemotherapy-resistant neuroblastoma

2010

$100,000

Children's Hospital Of Philadelphia

Dr. Grupp

Engineered T Cell Therapy For Recurrent Neuroblastoma & B Cell Malignancies

$100,000

Children's Hospital Of Philadelphia

Dr. Hogarty

Sirna based Kimome screen to id Mcl1 antagonists for resistant Tumors

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy, 2nd round of funding

$100,000

St Jude Children's Research Hospital

Dr. Bhojwani

CD-20 targeted immunotherapy for relapsed childhood neuroblastoma

$100,000

Texas Children's Cancer Center

Dr. Shohet

Therapy for relapsed neuroblastoma. P13k/Aktm tor pathway inhibition

$100,000

Texas Children's Cancer Center

Dr. Su

Therapy efficacy study for newly diagnosed brainstem gliomas

2009

$100,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Bite Therapy

$35,000

Texas Children's Cancer Center

Dr. Rabin

Novel therapy using JAK-STAT pathway inhibitors in childhood leukemias

$50,000

Texas Children's Cancer Center

Dr. Louis

A phase I/II study using allogenic tumor cell vaccination with oral metronomic cytoxan in patients with high-risk neuroblastoma

$150,000

Texas Children's Cancer Center

Two Grants

2008

$400,000

Memorial Sloan-Kettering Cancer Center

Dr. Cheung

Hu3f8 antibody treatment for neuroblastoma